Log In
BCIQ
Print this Print this
 

LentiGlobin HPV569 gene therapy

  Manage Alerts
Collapse Summary General Information
Company bluebird bio Inc.
DescriptionAutologous CD34+ stem cells transduced ex vivo with a lentiviral vector delivering the human beta globin gene
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Lentivirus
Latest Stage of DevelopmentPhase I/II
Standard IndicationThalassemia
Indication DetailsTreat sickle cell anemia and beta-thalassemia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today